Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1 (Excision Repair Cross-complementation Group 1)

NCT01524575 is registered in ClinicalTrials.gov with University of Hawaii as lead sponsor.

NCT NCT01524575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01524575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1 (Excision Repair Cross-complementation Group 1)
Lead sponsor
University of Hawaii
Phase
Phase 2
Overall status
Withdrawn
Start date
January 31, 2012
Completion date
January 31, 2014
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ercc1, metastatic pancreatic cancer